This page shows the latest prasugrel news and features for those working in and with pharma, biotech and healthcare.
Humalog is just one of Lilly’s big brands facing competition, along with erectile dysfunction therapy Cialis (tadalafil) and antiplatelet drug Effient (prasugrel), and the company recently announced sweeping job cuts
The Japanese drugmaker is already a major player in the thrombosis market with products such as Eli Lilly-partnered antiplatelet drug Effient (prasugrel) and recently-introduced NOAC Lixiana (edoxaban).
The drug is an intravenously-administered P2Y12 inhibitor - in the same class as AstraZeneca's Brilinta (ticagrelor) and Daiichi Sankyo/Eli Lilly's Effient (prasugrel) - and like its peers is moving
Cangrelor is a P2Y12 inhibitor - in the same class as AstraZeneca's Brilinta (ticagrelor) and Daiichi Sankyo/Eli Lilly's Effient (prasugrel) - and like its counterparts is aiming to tap into
Brilinta (sold as Brilique in Europe) also has competition in the form of Eli Lilly and Daiichi Sankyo's Effient (prasugrel), although the latter has been held back by a higher
on Lilly's Efient (prasugrel) to include people with acute coronary syndromes. ... Taking these factors into consideration, we are now recommending prasugrel as an option for more people with acute coronary syndromes than our previous guidance,” said
More from news
Approximately 0 fully matching, plus 26 partially matching documents found.
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...